Nordic Bioproducts Group

Nordic Bioproducts Group has commercialized its patented AaltoCell™ technology for the sustainable production of microcrystalline cellulose (MCC) and cellulose derivatives. Their Lappeenranta facility enables continuous, large-scale, low-carbon MCC manufacturing for use in pharmaceuticals, food, cosmetics, textiles, biocomposites, and more. The company’s process achieves significant reductions in chemical use (~69%), water (~95%), energy (~90%), and greenhouse gas emissions (~81%) compared to traditional methods. Their flagship product line—PURA Series MCC—is ISO 9001 and EXCiPACT certified for pharmaceutical applications.